Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track APGE with free AI briefings, catalyst countdowns, and dilution alerts.

APGE · Apogee Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Acquired. Apogee Therapeutics was acquired: the merger closed on Sep 3, 2026 and APGE was delisted. The data below is from before the deal. Read the filing
$1.3B Cash on Hand
61.2mo Cash Runway
7.3% Short Interest
$134.62 Analyst Target (5)
Follow APGE by email Get an email when APGE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APGE, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Opaganib (ABC294640) Carcinoma, Hepatocellular Phase 2 · NCT02939807 Withdrawn
APG777 Atopic Dermatitis Phase 2 · NCT06395948 Active not recruiting
APG990 Atopic Dermatitis Phase 1 · NCT07027527 Active not recruiting

Also used in these trials (approved or third-party drugs, not APGE's own candidates): Dupilumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APGE holds $1.3B in cash and short-term investments (as of Jun 30, 2026) and burns about $63.5M/quarter from operations, an estimated runway of 61.2 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APGE files for a raise →

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-03
filed 2026-09-03
Fairmount Funds Management LLC
Returned to issuer (D) 14,461 – –
2026-09-03
filed 2026-09-03
McKenna Mark C.
Returned to issuer (D) 20,000 – 0
2026-09-03
filed 2026-09-03
Shah Nimish P
Returned to issuer (D) 365,853 – –
2026-09-03
filed 2026-09-03
Shah Nimish P
Returned to issuer (D) 7,657 – –
2026-09-03
filed 2026-09-03
Shah Nimish P
Returned to issuer (D) 14,461 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full APGE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APGE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.